RxDoctor Payments Data

Brian McManus, MD

Cardiovascular Disease · Plymouth, MANPI 1669585899

Payments from drug & device makers

$255in general payments, 2019–2025

Across 15 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$67
  • Merck$53
  • Edwards Lifesciences$24
  • Pfizer$20
  • Amarin Pharma, Inc.$18
  • Kerecis Limited$16
  • plus $57 from 4 others

What the payments were for

  • Food & beverage$255100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$255 in reported general payments places this provider in the 25th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$486,888
Medicare patients
544
Services billed
5,296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban177$196,860
XareltoRivaroxaban84$99,967
JanuviaSitagliptin Phosphate40$38,595
OzempicSemaglutide22$20,701
JardianceEmpagliflozin16$19,303
Rosuvastatin Calcium400$19,152
EntrestoSacubitril/Valsartan14$15,560
Metoprolol Succinate690$14,595
LinzessLinaclotide12$7,925
Atrovent HfaIpratropium Bromide16$7,559
Atorvastatin Calcium596$6,871
SymbicortBudesonide/Formoterol Fumarate18$6,333
Pravastatin Sodium187$4,027
Losartan Potassium358$3,942
Wixela InhubFluticasone Propion/Salmeterol46$3,716

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$196,860177 claims
MerckJanuvia$53$38,59540 claims
Novo NordiskOzempic$13$20,70122 claims
NovartisEntresto$14$15,56014 claims
AstraZenecaSymbicort$67$6,33318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Plymouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →